Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioRestorative Therapies (BRTX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for BioRestorative Therapies (BRTX) over the last 14 years, with Q3 2025 value amounting to -$49308.0.

  • BioRestorative Therapies' Cash from Financing Activities changed N/A to -$49308.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year decrease of 7621.16%. This contributed to the annual value of $7.4 million for FY2024, which is 21417.81% up from last year.
  • According to the latest figures from Q3 2025, BioRestorative Therapies' Cash from Financing Activities is -$49308.0.
  • BioRestorative Therapies' Cash from Financing Activities' 5-year high stood at $21.1 million during Q4 2021, with a 5-year trough of -$126316.0 in Q4 2024.
  • In the last 4 years, BioRestorative Therapies' Cash from Financing Activities had a median value of $569069.0 in 2021 and averaged $3.3 million.
  • In the last 5 years, BioRestorative Therapies' Cash from Financing Activities crashed by 25205.42% in 2024 and then soared by 701534.69% in 2025.
  • Quarter analysis of 4 years shows BioRestorative Therapies' Cash from Financing Activities stood at $21.1 million in 2021, then plummeted by 99.61% to $83073.0 in 2023, then tumbled by 252.05% to -$126316.0 in 2024, then soared by 60.96% to -$49308.0 in 2025.
  • Its last three reported values are -$49308.0 in Q3 2025, $888138.0 for Q2 2025, and $1.1 million during Q1 2025.